Kymera Therapeutics, Inc.
Total Trades
92
Buys
12
Sells
47
Largest Trade
N/A
Insiders
14
Institutional Funds
193
Inst. Value
$1M+
Activist Filings
42
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Chadwick Jeremy G | COO | SELL | $500K+ | 6K | $86.54 | Mar 4, 2026 |
| Chadwick Jeremy G | COO | GRANT | N/A | 13K | — | Mar 4, 2026 |
| Gollob Jared | Chief Medical Offi… | SELL | $500K+ | 11K | $87.24 | Mar 4, 2026 |
| Gollob Jared | Chief Medical Offi… | GRANT | N/A | 18K | — | Mar 4, 2026 |
| Jacobs Bruce N. | CFO | GRANT | N/A | 18K | — | Mar 4, 2026 |
| Jacobs Bruce N. | CFO | SELL | $1M+ | 12K | $87.50 | Mar 4, 2026 |
| Booth Bruce | Director | SELL | $1M+ | 82K | $90.13 | Mar 4, 2026 |
| Mainolfi Nello | CEO | SELL | $1M+ | 30K | $90.26 | Feb 25, 2026 |
| Mainolfi Nello | CEO | EXERCISE | $50K–$100K | 30K | $2.08 | Feb 25, 2026 |
| Esposito Pamela | Director | SELL | $100K–$500K | 3K | $87.31 | Feb 20, 2026 |
| Esposito Pamela | Director | EXERCISE | $100K–$500K | 3K | $49.10 | Feb 20, 2026 |
| Esposito Pamela | Director | EXERCISE | $100K–$500K | 6K | $39.34 | Jan 20, 2026 |
| Esposito Pamela | Director | SELL | $100K–$500K | 6K | $67.91 | Jan 20, 2026 |
| Mainolfi Nello | CEO | EXERCISE | $50K–$100K | 30K | $2.08 | Dec 31, 2025 |
| Mainolfi Nello | CEO | SELL | $1M+ | 30K | $78.06 | Dec 31, 2025 |
| Esposito Pamela | Director | EXERCISE | $1M+ | 28K | $37.82 | Dec 17, 2025 |
| Esposito Pamela | Director | SELL | $1M+ | 28K | $82.16 | Dec 17, 2025 |
| Booth Bruce | Director | SELL | $1M+ | 237K | $91.72 | Dec 12, 2025 |
| BAKER BROS. ADVISORS LP | Director | BUY | $1M+ | 2.0M | $86.00 | Dec 11, 2025 |
| Albers Jeffrey W. | Director | SELL | $100K–$500K | 5K | $89.76 | Dec 8, 2025 |
| Albers Jeffrey W. | Director | EXERCISE | $50K–$100K | 5K | $14.18 | Dec 8, 2025 |
| Mainolfi Nello | CEO | EXERCISE | $100K–$500K | 100K | $2.08 | Dec 8, 2025 |
| Mainolfi Nello | CEO | SELL | $1M+ | 100K | $89.17 | Dec 8, 2025 |
| Gollob Jared | Chief Medical Offi… | SELL | $1M+ | 49K | $88.67 | Dec 8, 2025 |
| Gollob Jared | Chief Medical Offi… | EXERCISE | $100K–$500K | 49K | $5.33 | Dec 8, 2025 |
| Mainolfi Nello | CEO | SELL | $1M+ | 30K | $60.99 | Oct 29, 2025 |
| Mainolfi Nello | CEO | EXERCISE | $50K–$100K | 30K | $2.08 | Oct 29, 2025 |
| Jacobs Bruce N. | CFO | EXERCISE | $100K–$500K | 79K | $2.08 | Sep 17, 2025 |
| Jacobs Bruce N. | CFO | SELL | $1M+ | 79K | $50.00 | Sep 17, 2025 |
| Mainolfi Nello | CEO | SELL | $1M+ | 30K | $49.00 | Sep 16, 2025 |
| Mainolfi Nello | CEO | EXERCISE | $50K–$100K | 30K | $2.08 | Sep 16, 2025 |
| BVF PARTNERS L P/IL | Director | BUY | $1M+ | 317K | $44.00 | Jul 1, 2025 |
| BAKER BROS. ADVISORS LP | Director | BUY | $1M+ | 656K | $44.00 | Jul 1, 2025 |
| Ridloff Elena | Director | EXERCISE | $50K–$100K | 5K | $20.29 | Jun 11, 2025 |
| Ridloff Elena | Director | SELL | $100K–$500K | 5K | $50.00 | Jun 11, 2025 |
| Esposito Pamela | Director | SELL | $100K–$500K | 5K | $49.04 | Jun 3, 2025 |
| Esposito Pamela | Director | EXERCISE | $100K–$500K | 5K | $29.55 | Jun 3, 2025 |
| Ridloff Elena | Director | EXERCISE | $100K–$500K | 12K | $27.67 | Jun 3, 2025 |
| Ridloff Elena | Director | SELL | $500K+ | 12K | $46.10 | Jun 3, 2025 |
| Mainolfi Nello | CEO | SELL | $1M+ | 30K | $49.00 | Jun 3, 2025 |
| Mainolfi Nello | CEO | EXERCISE | $50K–$100K | 30K | $2.08 | Jun 3, 2025 |
| Albers Jeffrey W. | Director | EXERCISE | $50K–$100K | 6K | $10.34 | Jun 3, 2025 |
| Albers Jeffrey W. | Director | SELL | $100K–$500K | 6K | $49.00 | Jun 3, 2025 |
| Chadwick Jeremy G | COO | SELL | $50K–$100K | 3K | $29.30 | May 23, 2025 |
| Chiniara Ellen | Chief Legal Officer | SELL | $100K–$500K | 3K | $41.75 | Jan 6, 2025 |
| Esposito Pamela | Director | SELL | $100K–$500K | 3K | $49.00 | Dec 3, 2024 |
| Esposito Pamela | Director | EXERCISE | $50K–$100K | 3K | $29.55 | Dec 3, 2024 |
| Albers Jeffrey W. | Director | SELL | $100K–$500K | 5K | $49.10 | Aug 26, 2024 |
| Albers Jeffrey W. | Director | EXERCISE | $50K–$100K | 5K | $10.34 | Aug 26, 2024 |
| BAKER BROS. ADVISORS LP | Director | BUY | <$1K | 1 | $46.41 | Aug 22, 2024 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 193 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4.7M | $1M+ | SH |
| Siren, L.L.C. | 3.3M | $1M+ | SH |
| STATE STREET CORP | 2.2M | $1M+ | SH |
| Capital Research Global Investors | 1.6M | $1M+ | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2M | $1M+ | SH |
| ALLIANCEBERNSTEIN L.P. | 952K | $1M+ | SH |
| FEDERATED HERMES, INC. | 764K | $1M+ | SH |
| EVENTIDE ASSET MANAGEMENT, LLC | 626K | $1M+ | SH |
| DIMENSIONAL FUND ADVISORS LP | 548K | $1M+ | SH |
| Octagon Capital Advisors LP | 535K | $1M+ | SH |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 497K | $1M+ | SH |
| JENNISON ASSOCIATES LLC | 497K | $1M+ | SH |
| Pictet Asset Management Holding SA | 483K | $1M+ | SH |
| BRAIDWELL LP | 454K | $1M+ | SH |
| Alyeska Investment Group, L.P. | 372K | $1M+ | SH |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 284K | $1M+ | SH |
| Nextech Invest, Ltd. | 279K | $1M+ | SH |
| Deer Management Co. LLC | 231K | $1M+ | SH |
| TD ASSET MANAGEMENT INC | 221K | $1M+ | SH |
| First Turn Management, LLC | 206K | $1M+ | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
Wellington Management Group LLP
SC 13G/A · Feb 10, 2026
5.5%
4.4M shares
SC 13G/A · Jan 8, 2026
11.2%
8.9M shares
SC 13D/A · Dec 15, 2025
4.4%
3.6M shares
SC 13D/A · Dec 11, 2025
10.9%
8.7M shares
T. Rowe Price Associates, Inc.
SC 13G/A · Nov 14, 2025
7.1%
5.1M shares
SC 13G/A · Nov 5, 2025
8.2%
5.9M shares
Wellington Management Group LLP
SC 13G/A · Aug 12, 2025
7.7%
5.4M shares
SC 13G/A · Jul 18, 2025
5.4%
3.8M shares
SC 13D/A · Jul 1, 2025
9.5%
6.7M shares
Wellington Management Group LLP
SC 13G/A · May 12, 2025
9.2%
6.0M shares
SC 13G/A · May 12, 2025
6.8%
4.4M shares
SC 13G/A · Apr 30, 2025
8.1%
5.2M shares
Wellington Management Group LLP
SC 13G/A · Feb 10, 2025
8.2%
5.3M shares
SC 13G/A · Nov 14, 2024
6.4%
4.2M shares
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
SC 13G/A · Nov 14, 2024
10.3%
6.6M shares
SC 13G/A · Nov 14, 2024
10.0%
7.8M shares
SC 13G · Nov 12, 2024
7.9%
5.1M shares
Wellington Management Group LLP
SC 13G/A · Nov 8, 2024
7.2%
4.6M shares
SC 13D/A · Aug 22, 2024
9.3%
6.0M shares
SC 13D · Apr 1, 2024
9.8%
6.0M shares
SC 13G/A · Feb 14, 2024
6.8%
3.8M shares
The Vanguard Group - 23-1945930
SC 13G/A · Feb 13, 2024
6.7%
4.0M shares
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
SC 13G/A · Feb 12, 2024
10.1%
6.0M shares
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
SC 13G/A · Feb 12, 2024
9.6%
5.3M shares
SC 13G/A · Jan 29, 2024
6.4%
3.6M shares
STATE STREET CORPORATION I.R.S. IDENTIFICATION NO. OF THE ABOVE PERSON 04-2456637
SC 13G/A · Jan 23, 2024
3.4%
0 shares
SC 13G/A · Jan 10, 2024
10.8%
6.0M shares
BIOTECHNOLOGY VALUE FUND, L.P.
SC 13D/A · Jan 9, 2024
5.5%
3.2M shares
Vertex Pharmaceuticals Incorporated
SC 13D/A · Jun 5, 2023
0.0%
0 shares
SC 13G/A · Feb 14, 2023
9.2%
5.1M shares
SC 13G/A · Feb 14, 2023
4.9%
2.7M shares
SC 13G · Feb 14, 2023
5.2%
2.9M shares
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
SC 13G/A · Feb 14, 2023
8.0%
4.4M shares
SC 13G · Feb 14, 2023
7.0%
3.9M shares
SC 13G/A · Feb 1, 2023
6.1%
3.3M shares
BIOTECHNOLOGY VALUE FUND, L.P.
SC 13D/A · Aug 23, 2022
4.5%
2.5M shares
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
SC 13G/A · Jul 11, 2022
10.1%
5.2M shares
BIOTECHNOLOGY VALUE FUND, L.P.
SC 13D/A · Jun 1, 2022
4.3%
2.2M shares
SC 13G/A · Feb 14, 2022
5.0%
2.6M shares
T. ROWE PRICE ASSOCIATES, INC. 52-0556948
SC 13G · Feb 14, 2022
6.9%
3.6M shares
SC 13G/A · Feb 11, 2022
11.2%
5.8M shares
BIOTECHNOLOGY VALUE FUND, L.P.
SC 13D/A · Jan 31, 2022
3.7%
1.9M shares